Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) has issued an update.
Mayne Pharma Group Limited announced the cessation of 2,392 performance rights due to the lapse of conditional rights, as the conditions were not satisfied. This announcement highlights a minor adjustment in the company’s issued capital, reflecting internal administrative updates rather than significant market impact.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceutical products. The company primarily serves the Australian and international markets, leveraging its expertise in drug delivery technologies.
YTD Price Performance: -8.85%
Average Trading Volume: 2,261
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $229.3M
For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.